JP6679096B2 - Ｒａｇｅアプタマーおよびその用途 - Google Patents

Ｒａｇｅアプタマーおよびその用途 Download PDF

Info

Publication number
JP6679096B2
JP6679096B2 JP2015206555A JP2015206555A JP6679096B2 JP 6679096 B2 JP6679096 B2 JP 6679096B2 JP 2015206555 A JP2015206555 A JP 2015206555A JP 2015206555 A JP2015206555 A JP 2015206555A JP 6679096 B2 JP6679096 B2 JP 6679096B2
Authority
JP
Japan
Prior art keywords
rage
aptamer
sequence
seq
stranded dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015206555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016079184A5 (https=
JP2016079184A (ja
Inventor
昌一 山岸
昌一 山岸
圭 深水
圭 深水
祐一郎 東元
祐一郎 東元
孝憲 松井
孝憲 松井
顕正 田口
顕正 田口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kurume University
Original Assignee
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurume University filed Critical Kurume University
Publication of JP2016079184A publication Critical patent/JP2016079184A/ja
Publication of JP2016079184A5 publication Critical patent/JP2016079184A5/ja
Application granted granted Critical
Publication of JP6679096B2 publication Critical patent/JP6679096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015206555A 2014-10-21 2015-10-20 Ｒａｇｅアプタマーおよびその用途 Active JP6679096B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014214467 2014-10-21
JP2014214467 2014-10-21

Publications (3)

Publication Number Publication Date
JP2016079184A JP2016079184A (ja) 2016-05-16
JP2016079184A5 JP2016079184A5 (https=) 2018-11-29
JP6679096B2 true JP6679096B2 (ja) 2020-04-15

Family

ID=55957680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015206555A Active JP6679096B2 (ja) 2014-10-21 2015-10-20 Ｒａｇｅアプタマーおよびその用途

Country Status (1)

Country Link
JP (1) JP6679096B2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6964322B2 (ja) * 2017-03-13 2021-11-10 学校法人 久留米大学 ループス腎炎を処置または予防するための医薬組成物およびループス腎炎のバイオマーカー
JP7082804B2 (ja) * 2017-07-12 2022-06-09 学校法人 久留米大学 Ｒａｇｅアプタマーを含む癌を治療するための医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090023672A1 (en) * 2005-01-27 2009-01-22 Kurume University Age-2 aptamer
WO2007109749A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases
KR101595634B1 (ko) * 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
KR20120089863A (ko) * 2009-10-09 2012-08-14 사노피 “개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
EP2650013A1 (en) * 2012-04-10 2013-10-16 Deutsches Krebsforschungszentrum Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer

Also Published As

Publication number Publication date
JP2016079184A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
Lin et al. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy
Ruperto et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Wang et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy
Reiniger et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse
Chen et al. Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases
Tarabra et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes
Yanagita et al. Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis
Izzedine et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy
Chen et al. Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
JP2009522339A (ja) 痛風または偽痛風の新規な治療法
CN113677706B (zh) 肝毒性的治疗
Ghali et al. IL-33 induces type-2-cytokine phenotype but exacerbates cardiac remodeling post-myocardial infarction with eosinophil recruitment, worsened systolic dysfunction, and ventricular wall rupture
JP7330174B2 (ja) オートファジーをモジュレーションするための方法及び医薬組成物
CN103648531A (zh) 用于预防或治疗代谢综合症的方法
Umbarkar et al. Repurposing Nintedanib for pathological cardiac remodeling and dysfunction
WO2021231887A1 (en) Compositions and methods of detection of pre-symptomatic als
Bus et al. Endoglin mediates vascular endothelial growth factor-A–induced endothelial cell activation by regulating Akt signaling
Xia et al. Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus
JP6679096B2 (ja) Ｒａｇｅアプタマーおよびその用途
Yang et al. Activation of the α7nAChR by GTS-21 mitigates septic tubular cell injury and modulates macrophage infiltration
CN120957731A (zh) 用于治疗多囊肾病的修饰的寡核苷酸
Bao et al. Notoginsenoside R1 reduces acquired lymphedema and increases lymphangiogenesis by promoting VEGF-C expression via cAMP/PKA/CREB signaling
Wu et al. The influence of fasudil on the epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells from diabetic rats
JP5578498B2 (ja) 抗癌剤キット及び抗癌剤効果増強剤
Wang et al. Deletion of lymphotoxin-β receptor (LTβR) protects against acute kidney injury by PPARα pathway

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200312

R150 Certificate of patent or registration of utility model

Ref document number: 6679096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250